Martin Daniel C. 4
4 · Deciphera Pharmaceuticals, Inc. · Filed Oct 31, 2023
Insider Transaction Report
Form 4
Martin Daniel C.
Chief Commercial Officer
Transactions
- Award
Common Stock
2023-10-28+5,576→ 64,291 total - Sale
Common Stock
2023-10-30$12.02/sh−1,407$16,909→ 62,884 total
Footnotes (3)
- [F1]On February 15, 2023, the Reporting Person was granted restricted stock units ("RSUs"), which vest upon the satisfaction of three performance criteria. On October 28, 2023, the Issuer's Compensation Committee confirmed that performance criteria two had been met, resulting in the vesting of 5,576 RSUs.
- [F2]Includes 302 shares previously acquired under the Issuer's 2017 Employee Stock Purchase Plan.
- [F3]This sale was to cover tax liabilities in the vesting of RSUs.